SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024. "We are thrilled to welcome Anne and Jennifer to our board as we prep ...

OXFORD, United Kingdom, June 12, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announced plans to prioritize its pipeline to focus on the development of VTP-300 in CHB and VTP-1000 in celiac disease. The development of VTP-300 in CHB and VTP-1000 in celiac disease will be prioritized and the ongoing Phase 1 clinical trial of VTP-850 in prostate cancer will be completed. The Company ...

The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized. The pipeline prioritization is expected to result in a reduction in workforce of approximately 25% and an estimated extension to the cash runway into the second quarter of 2026. The decision follows the positive interim data from the two ongoing Phase 2 clinical trials presented at the European Association for the Study of the Liver (EASL) Congress on June 6, 2024. The data from the ongoing HBV003 and ...

In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the IM-PROVE II trial, conducted in partnership with Arbutus Biopharma, a statistically significant difference was observed in HBsAg levels between the VTP-300 treatment and placebo groups at 24- weeks post-end of treatment (EOT) and 84% ...

Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditure to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other factors that may adversely affect our business. The size of our future net losses will depend on the rate of future growth of our expenses combined with our ability to generate revenue. Our prior losses and expect ...

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments "So far in 2024 we have continued to make strides across our programs. Notably, we received clearance from the FDA on an IND to progress VTP-1000 in a first in human clinical trial in celiac disease, as well as clearance from the Australian Ethics Committee on this trial. We expect to begin our Phase 1 trial of VTP-1000 in participants with celiac disease in the coming months. Additionally, we reported topline fi ...

OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, announced its financial results for the first quarter of 2024 and provided an overview of the Company's progress. "So far in 2024 we have continued to make strides across our programs. Notably, we received clear ...

OXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, today announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer (CMO). "We are happy to welcome Dr. Hooftman to Barinthus Bio as our Chief Medical Officer. With his exper ...

Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events (AEs) or serious AEs (SAEs). Positive trends in clearance rate for both high-risk (hr)HPV (60%, Group 2) and cervical lesions (67%,Groups 2 and 5), were observed in the groups receiving the highest ChAdOx dose.Pooled data from the five different active dose groups demonstrated no statistically significant improvement in either hrHPV or cervical lesion clearance in comparison to the p ...

公司财务状况 - 公司截至2023年12月31日的累计亏损为1.766亿美元[336][336] - 公司2023年度净亏损为7,340万美元[336] - 公司截至2023年12月31日的现金及现金等价物为1.421亿美元[351][361] 产品候选者和研发 - 公司尚未从产品候选者中产生任何实质性收入[338] - 公司预计未来产品候选者的成功开发和商业化将带来重要收入[339] - 公司目前正在推进基于自有生物和合成平台的当前和未来产品候选，包括ChAdOx和MVA载体，SNAP-TI，SNAP-CI和其他技术，通过临床开发[350] 资金需求和风险 - 公司可能会进行收购或未来战略合作，增加资本需求，稀释股东权益，导致公司负债或承担潜在责任，并面临其他风险[344] - 公司预计未来资金需求将取决于多个因素，包括产品候选人的临床试验进展、市场批准的成本和时间、商业化活动的成本等[362] 市场批准和监管 - 公司的产品候选药物获得BLA批准后应符合12年的排他性期限[498] - FDA或类似的外国监管机构批准公司的产品候选人后，将受到广泛和持续的监管要求[517] - 公司的业务活动将受到《外国腐败行为法》（FCPA）和其他司法管辖区的类似反贿赂和反腐败法律的约束[529]